Standard BioTools (LAB) and SomaLogic (SLGC) to Combine in All-Stock Merger
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools
October 4, 2023 8:00 AM EDTActivates Standard BioTools strategy to unlock value in underserved portion of $100 billion industry
Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights
Expands commercial reach with substantial cross-selling opportunities and complementary offerings
Generates estimated $80 million of annual cost synergies by 2026 and enhanced combined path to profitability1
Estimated combined cash of over $500 million at close2 creates industry-leading balance sheet to fund growth initiatives
Standard BioTools increases... More
